Psoriasis, a life-long systemic inflammatory disease, is said to significantly affect the patients’ quality of life, both physically and emotionally. Cosentyx is claimed to be the first and
SAB-176 is a novel anti-influenza human immunoglobulin G (IgG) immunotherapy designed to address the limitations of current treatment for severe seasonal influenza. This fully human polyclonal antibody therapeutic
MDS is a rare form of bone marrow-related cancer, which will be resulted due to irregular blood cell production within the bone marrow. Pevonedistat, a first-in-class NEDD8-activating enzyme
Alpna Seth, PhD, a leader in the global biotechnology industry, is President and Chief Executive Officer of Nura Bio. The Column Group led the company’s $73 million Series
The phase III COVACTA study of tocilizumab did not reach its primary endpoint of improved clinical status in hospitalised adult patients with severe Covid-19 associated pneumonia. Roche’s trial
The US technology company signed a letter of interest (LOI) with the DFC to secure a loan to establish Kodak Pharmaceuticals, a new business unit that will engage
AI Therapeutics is a biopharmaceutical company that develops novel therapies identified through a proprietary artificial intelligence algorithm for matching drugs to new indications (Guardian Angel). The randomized, double-blind,
Both companies have decided to advance their BNT162b2 vaccine candidate into the phase 2/3 study at a 30µg dose level in a two-dose regimen after an extensive assessment
An earlier award from BARDA for up to $483 million was entered into to support the scale up of mRNA-1273 and clinical development, originally with a smaller anticipated
Tecartus, earlier known as KTE-X19, is claimed to be the first and only approved chimeric antigen receptor (CAR) T cell therapy to treat relapsed or refractory MCL. Tecartus,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.